Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Ann Allergy Asthma Immunol ; 127(4): 451-455.e1, 2021 10.
Article in English | MEDLINE | ID: covidwho-1275118

ABSTRACT

BACKGROUND: Oral immunotherapy (OIT) is effective in desensitizing patients with food allergy but adverse reactions limit its use. OBJECTIVE: To study the effect of the coronavirus disease 2019 lockdown in Israel between March 15, 2020, and April 30, 2020, on the incidence of home epinephrine-treated reactions. METHODS: All patients who were in the up-dosing phase of OIT for greater than or equal to 1 month during the lockdown, or a respective period in years 2015 to 2019, were studied. The incidence of home-epinephrine treated reactions during the 2020 lockdown was compared with that in the respective period in 2015 to 2019 and to periods before and after the lockdown. RESULTS: A total of 1163 OIT treatments were analyzed. Two epinephrine injections occurred during 2020 (0.7%) compared with 29 injections (3.28%) during 2015 to 2019 (P = .03). Patients treated in 2020 were older (8.1 vs 7 years, P < .01) and had a significantly lower single highest tolerated dose (12 vs 20 mg protein, P < .01). The rate of milk-OIT was lower (P = .01), but the total number of milk treatments was higher (99 vs 71 to 82) in 2020 compared with 2015 to 2019. On multivariate analysis, treatments during the 2020 lockdown were performed in older patients (P = .001), primarily for nonmilk (P = .03), began with a lower single highest tolerated dose (P = .006), and were associated with significantly less home epinephrine-treated reactions (P = .05) compared with those in 2015 to 2019. Patients treated in 2020 experienced more epinephrine-treated reactions in adjacent periods before (n = 8) and after (n = 6) the lockdown. CONCLUSION: The lower rate of home epinephrine-treated reactions during the coronavirus disease 2019 lockdown in Israel suggests that potentially avoidable triggers contribute significantly to the rate of adverse reactions during OIT.


Subject(s)
Desensitization, Immunologic/adverse effects , Epinephrine/administration & dosage , Epinephrine/adverse effects , Food Hypersensitivity/drug therapy , Administration, Oral , Adolescent , Adult , Allergens/immunology , COVID-19/epidemiology , Child , Child, Preschool , Female , Humans , Male , SARS-CoV-2/pathogenicity , Young Adult
2.
J Allergy Clin Immunol Pract ; 8(9): 2851-2857, 2020 10.
Article in English | MEDLINE | ID: covidwho-670976

ABSTRACT

The SARS-CoV2 pandemic has prompted a re-evaluation of our current practice of medicine. The seemingly abrupt worldwide spread of this disease resulted in immediate changes and a reduction in many allergy-focussed services and procedures. The reality of the long-term circulation of this virus in our communities requires us to evolve as a specialty. In this article, we outline current and future challenges in the management of food allergy in light of coronavirus disease 2019 (COVID-19). We focus on infant food allergy prevention, management of anaphylaxis, accurate diagnosis with oral food challenges, and active management of food allergy with oral immunotherapy. This article identifies the challenges of conflicting guidelines, shortcomings of acute management approaches, and inherent system deficiencies. We offer perspectives and strategies that can be implemented now, including an evaluation of virtual care and telemedicine for the management of food allergy. The use of a shared decision-making model results in novel approaches that can benefit our patients and our specialty for years to come. COVID-19 has forced us to re-evaluate our current way of thinking about food allergy management to better treat our patients.


Subject(s)
Betacoronavirus , Coronavirus Infections/prevention & control , Food Hypersensitivity/diagnosis , Food Hypersensitivity/drug therapy , Immunotherapy/methods , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Telemedicine/methods , Anaphylaxis/complications , Anaphylaxis/drug therapy , COVID-19 , Food Hypersensitivity/complications , Humans , SARS-CoV-2
3.
J Allergy Clin Immunol Pract ; 8(9): 2845-2850, 2020 10.
Article in English | MEDLINE | ID: covidwho-718811

ABSTRACT

In the wake of the COVID-19 pandemic and massive disruptions to daily life in the spring of 2020, in May 2020, the Centers for Disease Control (CDC) released guidance recommendations for schools regarding how to have students attend while adhering to principles of how to reduce the risk of contracting SARS-CoV-2. As part of physical distancing measures, the CDC is recommending that schools who traditionally have had students eat in a cafeteria or common large space instead have children eat their lunch or other meals in the classroom at already physically distanced desks. This has sparked concern for the safety of food-allergic children attending school, and some question of how the new CDC recommendations can coexist with recommendations in the 2013 CDC Voluntary Guidelines on Managing Food Allergy in Schools as well as accommodations that students may be afforded through disability law that may have previously prohibited eating in the classroom. This expert consensus explores the issues related to evidence-based management of food allergy at school, the issues of managing the health of children attending school that are acutely posed by the constraints of an infectious pandemic, and how to harmonize these needs so that all children can attend school with minimal risk from both an infectious and allergic standpoint.


Subject(s)
Betacoronavirus , Coronavirus Infections/prevention & control , Epinephrine/therapeutic use , Food Hypersensitivity/drug therapy , Food Hypersensitivity/prevention & control , Inservice Training/methods , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , School Health Services , Adolescent , Adrenergic alpha-Agonists/therapeutic use , Anaphylaxis , COVID-19 , Centers for Disease Control and Prevention, U.S. , Child , Educational Personnel/education , Humans , Practice Guidelines as Topic , SARS-CoV-2 , Schools , United States
SELECTION OF CITATIONS
SEARCH DETAIL